{"id":"NCT02678286","sponsor":"Baudax Bio","briefTitle":"Evaluation of N1539 Following Abdominoplasty Surgery","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of N1539 Following Abdominoplasty Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01","primaryCompletion":"2016-10","completion":"2016-11","firstPosted":"2016-02-09","resultsPosted":"2018-02-14","lastUpdate":"2018-02-14"},"enrollment":219,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pain, Post-operative"],"interventions":[{"type":"DRUG","name":"N1539","otherNames":["Intravenous meloxicam"]},{"type":"DRUG","name":"Intravenous Placebo","otherNames":[]}],"arms":[{"label":"N1539 30mg","type":"EXPERIMENTAL"},{"label":"IV Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the analgesic efficacy of N1539 in subjects with acute moderate to severe pain following abdominoplasty surgery.","primaryOutcome":{"measure":"Summed Pain Intensity Difference Over the First 24 Hours (SPID24)","timeFrame":"24 Hours","effectByArm":[{"arm":"N1539 30 mg","deltaMin":-4262.1,"sd":214.19},{"arm":"IV Placebo","deltaMin":-3535.7,"sd":215.05}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0145"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":20},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":["30737315"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":110},"commonTop":["Nausea","Headache","Vomiting","Dizziness","Decreased appetite"]}}